Clinical Trials for Natera

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Circulating Tumor DNA Response In Urothelial Cancer

Feasibility Trial of Combination of Obstetrical Carrier Screening and Hereditary Cancer Screening

ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness

Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC)

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

A Prospective Study Investigating the Relationship Between Minimal Residual Disease Detection, Monitoring Frequency, and Prognosis in Non-small Cell Lung Cancer Patients Eligible for Curative Treatment.

Effect of Capivasertib on ctDNA in ER Positive Breast Cancer

Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.

A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy

Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer

Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection

EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)

Trifecta-Lung cfDNA-MMDx Study

Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer

Evaluating Novel Therapies in ctDNA Positive GI Cancers

LAMBDA 002 (Lung Registry) Study

Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

ctDNA Assay in Patients With Resectable Pancreatic Cancer

Longitudinal ctDNA Surveillance for Older Women With ER+ Breast Cancer Who Omit Surgery

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma

Prospera Test Evaluation in Cardiac Transplant (ProTECT)

Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Trifecta-Heart cfDNA-MMDx Study

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy

Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA)

BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer

Trifecta-Kidney cfDNA-MMDx Study

The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)